NCT03934359: A Study to Evaluate the Safety, Tolerability of DN1508052-01 to Advanced Solid Tumors

NCT03934359
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic central nervous system (CNS) metastases or carcinomatous meningitis- see trial for details
https://ClinicalTrials.gov/show/NCT03934359

Comments are closed.

Up ↑